Ropivacaine Hydrochloride Injection Shortage
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported a current shortage of Ropivacaine Hydrochloride Injection, affecting various presentations, with some available and others unavailable as of the latest update.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Ropivacaine Hydrochloride Injection.
What's in Shortage
The generic drug name is Ropivacaine Hydrochloride Injection. Brand names include NAROPIN and ROPIVACAINE HYDROCHLORIDE. It is available in injection form and falls under the therapeutic category of Anesthesia. The shortage status is current, with the initial posting date of 03/23/2018 and last updated on 04/02/2026.
Which Manufacturers Are Affected
Fresenius Kabi USA, LLC is the affected manufacturer. Their availability varies by presentation: some, like Naropin Injection 10 mg/1 mL (NDC 63323-288-11), are available, while others, such as Naropin Injection 2 mg/1 mL (NDC 63323-285-63), are unavailable with expected recovery listed as TBD. Contact information for the manufacturer is 888-386-1300.
Why There's a Shortage
No specific reason was given for the shortage.
What Patients Should Do
Patients should speak with their pharmacist or healthcare provider to check availability and discuss options. They can contact the manufacturer at 888-386-1300 for more details. Please remember that patients should consult their healthcare provider for any medical advice and not make changes without professional guidance.
Source
This information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,239 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.